Skip to main content
Premium Trial:

Request an Annual Quote

BF-BIOlabs Licenses OGT's Array Patents

NEW YORK (GenomeWeb News) – Oxford Gene Technology has licensed the rights to make and market certain oligonucleotide microarrays using the company’s Southern array patents to BF-BIOlabs, OGT said today.
 
Under the license, BF-BIOlabs will be able to sell arrays and array-based services for identifying genes, SNPs, and gene expression analysis.
 
OGT said the license will remain valid for the lifetime of the patents. Financial terms of the agreement were not released.
 
BF-BIOlabs offers services for microarray experiments, chip readout, and data analysis. In addition to patent licensing, OGT also focuses on digital microarrays, single cell analysis, cytogenetetics products, and high-throughput microarray services.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.